CGEN-855B

CGEN-855B is a therapeutic candidate, specifically a monoclonal antibody, designed to target a novel soluble splice variant of the B7-H3 (CD276) immune checkpoint molecule. Discovered by Compugen Ltd. through its proprietary computational discovery platform, the CGEN-855B protein variant is a member of the B7 family of costimulatory molecules that regulate T-cell activation. B7-H3 is frequently overexpressed in various solid tumors and plays a significant role in tumor immune evasion. CGEN-855B was identified as a potential diagnostic marker and therapeutic target due to its distinct expression profile in malignancies. While Compugen initially pursued the development of antibodies against this variant for cancer immunotherapy, the program is not currently featured in the company's active clinical-stage pipeline, suggesting it remains in early preclinical research or has been deprioritized in favor of other checkpoint targets such as PVRIG and TIGIT.